In-Vitro Permeation Test Data Analysis with MS Excel as per FDA’s Guidance

News
Article
Pharmaceutical TechnologyPharmaceutical Technology, July 2023
Volume 47
Issue 7
Pages: 30–35

FDA’s new guidance on in-vitro permeation test studies published in October 2022 gives technical and statistical requirements for conducting these tests to compare topical generic drugs with their reference products.

Skin Prick Allergy Testing |Image Credit: © Microgen - © Microgen - stock.adobe.com

Microgen - stock.adobe.com

This article describes the data processing procedures and FDA statistical mathematics of an in-vitro permeation test (IVPT) study for evaluating a generic topical drug product against its reference product. IVPT-Stat v2.0, a tool composed of two Microsoft (MS) Excel files, is provided in the present paper to perform FDA statistic bioequivalence analysis with IVPT data (i.e., maximum flux [Jmax] and total cumulative amount permeated [denoted as AMT]) of the test and reference topical drug products. The algorithms and use of IVPT-Stat v2.0 are also elucidated with examples. As a MS Excel-based tool, IVPT-Stat v2.0 is user friendly and can be easily run by most industry practitioners and should make IVPT data analysis easy.

Click here for a PDF of this article.

Click here for Table IV.

Peer-reviewed research

Submitted: Feb. 17, 2023
Accepted: March 29, 2023

About the author

Lei Lei, PhD, ryan.lei@cutiatx.com, is the senior vice-president R&D of Cutia Therapeutics, Shanghai, China.

Article details

Pharmaceutical Technology
Vol, 47, No. 7
July 2023
Pages: 30–35

Citation

When referring to this article, please cite it as Lei, L. In-Vitro Permeation Test Data Analysis with MS Excel as per FDA’s Guidance. Pharmaceutical Technology 2023, 47 (7), 30–35.

Recent Videos
Drug Digest: Strategic Partnerships
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.